Company intelligence / Profile preview
Acacia Pharma Group Plc
Cambridge, United Kingdomacaciapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Acacia Pharma had two FDA-approved products: BARHEMSYS (amisulpride injection) for postoperative nausea & vomiting and BYFAVO (remimazolam for injection) for procedural sedation. The company was acquired by Eagle Pharmaceuticals in June 2022.
- Therapeutic areas
- GastroenterologyOncologyOther
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Cosmo Pharmaceuticals
Beyond the preview
Go deeper on Acacia Pharma Group Plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acacia Pharma Group Plc.